Nitrosoprodenafil

Nitrosoprodenafil is a synthetic drug that is structurally similar to sildenafil, a medication used to treat erectile dysfunction. It is classified as a designer drug and is often found in products marketed as dietary supplements for sexual enhancement. Nitrosoprodenafil is not approved by the Food and Drug Administration (FDA) due to its potential health risks.

History

Nitrosoprodenafil was first identified in 2009 during the testing of a variety of dietary supplements by the FDA. The agency found that the substance was being used as a substitute for sildenafil in these products, despite not being approved for use in humans.

Pharmacology

Like sildenafil, nitrosoprodenafil works by inhibiting the enzyme phosphodiesterase type 5 (PDE5). This enzyme is responsible for the breakdown of cyclic guanosine monophosphate (cGMP), a substance that relaxes smooth muscle and increases blood flow. By inhibiting PDE5, nitrosoprodenafil allows cGMP to remain active longer, thereby enhancing erectile function.

However, nitrosoprodenafil differs from sildenafil in that it also releases nitric oxide (NO), a gas that further enhances the relaxation of smooth muscle and increases blood flow. This dual action makes nitrosoprodenafil potentially more potent than sildenafil.

Health Risks

The use of nitrosoprodenafil carries several health risks. Because it is not regulated by the FDA, the exact composition and purity of products containing this substance are unknown. This can lead to unpredictable effects and potential harm.

Furthermore, the release of nitric oxide by nitrosoprodenafil can lead to a dangerous drop in blood pressure, especially in individuals taking nitrates for heart disease. Other potential side effects include headache, flushing, dyspepsia, and visual disturbances.

Legal Status

In the United States, nitrosoprodenafil is classified as a designer drug and is illegal to sell, manufacture, or possess. The FDA has issued several warnings about dietary supplements containing this substance and has taken action against companies marketing these products.

• 
  Proposed structures of Nitrosoprodenafil